Estrategia en Cáncer del Sistema Nacional de Salud

Objectives

Spain’s National Health System Cancer Strategy, updated in 2010 following approval by the Interterritorial Council in October 2009, seeks to reduce the population burden of cancer and geographical inequalities through quality, equity and cohesion. It aims to optimise prevention, early detection, diagnosis, treatment, information and research, using shared objectives and recommendations applicable across the National Health System.[1][2][3]

• Strengthen health promotion and protection by reducing tobacco use, risky alcohol consumption, unhealthy diets, obesity, physical inactivity, occupational exposures and environmental carcinogens.[4][5][6]
• Maintain and improve early detection for breast cancer, cervical cancer and colorectal cancer, with population-based breast screening for women aged 50 to 69 and phased colorectal screening for women and men aged 50 to 69.[7][8]
• Improve adult cancer care through timely diagnostic confirmation, evidence-based multidisciplinary treatment, coordinated follow-up, clinical guidelines, case management and assessment of outcomes.[9][10][11]
• Provide comprehensive care for children and adolescents with cancer, integrating medical, psychosocial, educational, rehabilitative and survivorship support for patients and families.[12][13]
• Guarantee comprehensive palliative care for people with advanced or terminal cancer and their families, respecting autonomy, relieving suffering and addressing physical, psychological, social and spiritual needs.[14][15]
• Improve quality of life through psycho-oncology, physical rehabilitation, nutritional support, social and occupational reintegration, and longer-term support for survivors.[16][17][18]
• Strengthen cooperative, multidisciplinary cancer research spanning basic, clinical, epidemiological, translational and applied research, alongside stable research teams, infrastructure and information systems.[19][20][21]

Implementation

Implementation relies on cooperation between the Ministry of Health and Social Policy, autonomous communities, scientific societies, patient associations, professional experts and research bodies. The Interterritorial Council approves the Strategy and evaluations; Technical and Institutional Committees develop, assess and review objectives, indicators and recommendations, supported by the Technical Secretariat and the Monitoring and Evaluation Committee.[22][23][24][25]

• Coordinate prevention through national and regional plans, legislation, public-health measures, targeted interventions and health promotion. Tobacco control combines smoke-free environments, advertising restrictions, taxation, cessation support and action focused on young people, women and marginalised populations.[26][27]
• Deliver screening through organised population programmes, quality assurance, information systems and the Spanish Cancer Screening Programmes Network. Autonomous communities are expected to provide recruitment, diagnostic referral and treatment capacity, while genetic-counselling units assess people at hereditary cancer risk.[7][28][8]
• Organise adult treatment through multidisciplinary tumour committees, tumour-specific clinical guidelines, named professional references and nurse case managers. Diagnostic pathways should support confirmation of well-founded breast or colorectal cancer suspicion within 15 days, and treatment intervals should be reviewed annually.[10][29][11]
• Deliver paediatric cancer services through autonomous-community-designated multidisciplinary oncology units, referral arrangements and national or international protocols. Units should support education and psychosocial development, register cases in the National Registry of Childhood Tumours, and refer highly specialised cases when necessary.[30][31]
• Integrate palliative care across primary, specialised and social care, with services organised around local needs, interdisciplinary teams, professional training and patient-centred decision-making.[32][33]
• Develop research through the Carlos III Health Institute, Cooperative Health Research Thematic Networks, accredited health-research institutes, cooperative clinical-trial structures, tumour banks, cancer registries and national and international partnerships.[34][35][36]

Evaluation is intended as a systematic, continuous improvement process using National Health System information, questionnaires agreed with strategy committees, autonomous-community data, audits, national health surveys, hospital discharge records, population-based cancer registries and the National Registry of Childhood Tumours. It covers the pathway from prevention to quality of life, although information gaps remain for ambulatory care, coordination and organisational effectiveness.[37][38][39]

• Monitor prevention through smoking prevalence, age of smoking initiation, obesity, alcohol-risk consumption, diet and physical-activity measures, with sex-disaggregated analysis where possible.[40][41][42][43]
• Assess screening through participation, coverage, additional examinations, detection rates, test positivity and quality indicators. Stated targets include at least 70% participation in breast screening, 70% cervical-screening coverage among women aged 30 to 60, and 50% national colorectal-screening coverage among people aged 50 to 69 by 2015.[7][28][8][44][45]
• Measure care quality through stage-specific survival, recurrence, surgical mortality, conservative breast surgery, treatment intervals, tumour-committee activity and audits of clinical records.[29][11][46][47]
• Track cancer outcomes through incidence, mortality, premature mortality and five-year observed survival, using European-standard age adjustment where appropriate and disaggregation by autonomous community and sex.[48][49][50]
• Review research capacity through cooperative-group participation, scientific publications, peer review, periodic centre assessment and clinical-trial outputs.[19][51][48]

The Strategy identifies resource needs for screening capacity, oncology staffing, radiotherapy, psychosocial care, rehabilitation, palliative care and research infrastructure, but does not provide an overall implementation budget or financing plan.[52][53][17][21]

Monitoring & Evaluation

The Strategy establishes a continuous evaluation approach intended to generate valid, reliable and useful information for decision-making and continuous improvement across the cancer pathway, from prevention and early detection to treatment, palliative care and quality of life.[21][37]It combines routine National Health System information with data specifically collected from autonomous communities through questionnaires agreed by the Monitoring and Evaluation Committee.[25][38]

• Use a four-year evaluation cycle, with an interim assessment after two years, technical review by the Technical Committee and formal approval of evaluation reports by the Interterritorial Council of the National Health System.[22][23][24]
• Collect information from autonomous communities, the Health Information Institute, national health surveys, hospital discharge records, clinical-record audits, cancer registries and screening-programme networks.[23][38][39]
• Address information gaps in primary care, specialist ambulatory care, coordination and organisational effectiveness through computerised clinical records and additional committee-agreed qualitative information.[37][38]
• Monitor prevention through tobacco prevalence, age of smoking initiation, obesity, physical activity and risky alcohol consumption, with results disaggregated by sex and autonomous community where possible.[40][41][42][43]
• Assess screening programmes through participation, coverage, further investigations, detection rates and quality-assurance indicators. Breast-screening participation is expected to reach at least 70%; cervical-screening coverage is targeted at 70% of women aged 30 to 60 within the preceding five years; colorectal screening is targeted to reach 50% national coverage among people aged 50 to 69 by 2015.[7][28][8]
• Report colorectal-screening participation biennially by autonomous community and report positive-test, high-risk adenoma and invasive-cancer detection indicators annually through the Spanish Cancer Screening Programmes Network.[54][45]
• Track adult cancer care through diagnostic and treatment intervals, multidisciplinary protocols, tumour-committee activity, breast-conserving surgery, and mortality following selected complex cancer operations.[9][10][29][55][47]
• Require hospitals treating cancer to evaluate stage-specific survival, recurrence and surgical mortality within 30 days or during the same admission, supported by electronic clinical records and hospital registries for common cancers.[30]
• Monitor palliative care through organisational reports, directories of specialised services, dedicated beds per 1,000 inhabitants, publicly funded research projects and accredited workforce training.[56][57][58]
• Measure psychological support, rehabilitation and research capacity through hospital audits, dedicated support staffing, patient records, accredited cooperative groups and cancer publications.[40][57][59][48]
• Use population-based cancer registries, mortality statistics and the National Registry of Childhood Tumours to monitor incidence, mortality, premature mortality and observed five-year survival.[48][49][50]

Accountability is principally exercised through the Monitoring and Evaluation Committee, Technical Committee, autonomous communities and Interterritorial Council, while indicator ownership is distributed among the Ministry of Health and Social Policy, National Statistics Institute, Carlos III Health Institute and regional authorities.[23][40][41]Several sections nevertheless do not specify detailed reporting schedules, complete indicator specifications or formal accountability procedures.[60][37]

Costing & Financing

The Strategy does not provide an overall budget, financing plan, funding-gap estimate or economic assumptions for cancer control.[60][7][37]Resource requirements are identified across screening, clinical care, palliative care and research, but most are not quantified.[4][52][61][21]

• Require adequate resources for population screening, diagnostic confirmation, treatment capacity, confirmatory colonoscopy and screening information systems, without specifying allocations or funding sources.[4][62][9][8]
• Identify shortages in specialised oncology staff, psychosocial care, rehabilitation, nutrition and radiotherapy equipment, alongside unequal access to specialist services; newer diagnostics and treatments are recognised as more effective but more expensive.[52][53][63]
• Describe palliative care as requiring high quality at reasonable cost, but provide no expenditure, funding mechanism or allocation.[64]
• Identify low and unstable cancer-research financing as a major weakness, particularly for centre infrastructure, technical personnel and sustained tumour-bank capacity.[19][65][36]
• Report direct Spanish cancer-research investment of 38 million euros in 2004, compared with a reported European average of 3.9 million euros, and identify investment below one euro per inhabitant and 0.0048% of gross domestic product.[66]
• Report specific funding of 30 million euros for the International Alliance for Regenerative Medicine, 15 million euros for the Ultra-Sequencing Platform and 10 million euros for the International Cancer Genome Consortium.[65]
• Report an annual figure of 6,763,606 euros for the 2003-2006 oncology Cooperative Health Research Thematic Network of Cancer Centres.[67]
• Call for stable administrative and economic support for cooperative cancer-research networks, dedicated research space and financing mechanisms for an inter-regional research network, without quantified commitments.[68][69][21]
• Characterise tobacco cessation advice, dedicated consultations, nicotine replacement therapy, alcohol screening and brief intervention as cost-effective, but provide no monetary estimates.[70][27][5]

Economic evidence is otherwise limited to contextual estimates, including less than 1% of health expenditure allocated to health-promotion strategies by European Union member states in 1997 and an estimate that a 10% global tobacco-price increase could avert more than 10 million deaths.[71][70]